ArticleRadiation oncology (London, England)2026
Radiotherapy with versus without concurrent immunotherapy following neoadjuvant chemoimmunotherapy in unresectable locally advanced esophageal squamous cell carcinoma.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo evaluate the impact on survival outcomes of adding concurrent immunotherapy to radiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma following neoadjuvant chemoimmunotherapy. MATERIALS AND
methodsWe included patients with stage II–IVA ESCC treated between January 2013 and May 2024. Survival was compared between the radiotherapy without concurrent immunotherapy and radiotherapy with concurrent immunotherapy groups.
resultsOf the 91 enrolled patients, 35 received radiotherapy without concurrent immunotherapy and 56 received radiotherapy with concurrent immunotherapy. Median overall survival was worse in the radiotherapy without concurrent immunotherapy group compared to the radiotherapy with concurrent immunotherapy group (18 vs. 41 months; hazard ratio = 0.39, 95% confidence interval: 0.18–0.82; P = 0.013). In contrast, no differences were observed in median disease-free survival, locoregional recurrence-free survival, or distant metastasis-free survival between the two groups. Grade ≥ 3 leukopenia and neutropenia occurred more frequently in the concurrent immunotherapy group.
conclusionIn this real-world cohort, concurrent immunotherapy was associated with improved overall survival in patients with unresectable locally advanced esophageal squamous cell carcinoma who received prior neoadjuvant chemoimmunotherapy. These findings are hypothesis-generating and highlight the need for prospective randomized trials to validate the optimal integration of immunotherapy in this multimodal treatment sequence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.